Status:
COMPLETED
Obstructive Sleep Apnea and Telomere Length
Lead Sponsor:
Associação Fundo de Incentivo à Pesquisa
Conditions:
Obstructive Sleep Apnea
Eligibility:
MALE
35-65 years
Phase:
PHASE2
Brief Summary
Obstructive sleep apnea (OSA) is a highly prevalent and morbid sleep disorder. Among the factors associated with its pathophysiology, the role of intermittent hypoxia stands out, contributing to the d...
Eligibility Criteria
Inclusion
- body mass index (BMI) of less than 35kg/m2
- age between 35 and 65 years
- diagnosed by laboratory polysomnography with moderate to severe OSA (apnea-hypopnea index, AHI≥20 events/hour of sleep)
Exclusion
- illiteracy
- participants with more than 50% of the respiratory events obtained in the polysomnography exam being central apneas
- participants with central AHI\>5 events/hour of sleep
- participants with sleepiness, measured by the Epworth sleepiness scale≥14
- participants with severe otorhinolaryngological diseases that preclude the use of CPAP (severe nasal septum deviation, severe nasal turbinate hypertrophy, marked palatine and/or adenoid hypertrophy)
- abuse of alcohol or chronic use of psychoactive drugs
- participants with decompensated clinical, neurological or psychiatric illness
- participants with other sleep disorders; participants who had already undergone previous OSA treatments
Key Trial Info
Start Date :
July 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2022
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04872816
Start Date
July 5 2018
End Date
April 30 2022
Last Update
May 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universidade Federal de São Paulo
São Paulo, Brazil